Abstract
The aim of this study was to create and characterize constitutively active mutant (CAM) histamine H1 receptors (H1R) using random mutagenesis methods to further investigate the activation process of the rhodopsin-like family of G protein-coupled receptors (GPCRs). This approach identified position 6.40 in TM 6 as a “hot spot” because mutation of Ile6.40420 either to Glu, Gly, Ala, Arg, Lys, or Ser resulted in highly active CAM H1Rs, for which almost no histamine-induced receptor activation response could be detected. The highly conserved hydrophobic amino acid at position 6.40 defines, in a computational model of the H1R, the asparagine cage motif that restrains the side chain of Asn7.49 of the NPxxY motif toward transmembrane domain (TM 6) in the inactive state of the receptor. Mutation of the asparagine cage into Ala or Gly, removing the interfering bulky constraints, increases the constitutive activity of the receptor. The fact that the Ile6.40420Arg/Lys/Glu mutant receptors are highly active CAM H1Rs leads us to suggest that a positively charged residue, presumably the highly conserved Arg3.50 from the DRY motif, interacts in a direct or an indirect (through other side chains or/and internal water molecules) manner with the acidic Asp2.50··Asn7.49 pair for receptor activation.
Footnotes
-
This work was supported by the European Community (LSHB-CT-2003-503337), Ministerio de Educación y Ciencia (SAF2006-04966), and Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR2005-00390).
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; CAM, constitutively active mutant; TM, transmembrane domain; H1R, H1 receptor; R-SAT, receptor selection and amplification technology; NF-κB, nuclear factor κB; PCR, polymerase chain reaction; DMEM, Dulbecco's modified essential medium.
-
↵1 Current affiliation: Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.
-
↵2 Current affiliation: Merck Serono, Boston, Massachusetts.
- Received May 28, 2007.
- Accepted October 16, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|